Brecon Pharmaceuticals, a UK supplier of packaging and clinical trials supplies services, has appointed Peter Belden as managing director.
Pharmaceutical Development Services (PDS), a quality services and regulatory affairs consultancy, is expanding its team of associates with the addition of Paul Butler and Martin Slade.
Chiltern International, a global CRO, has appointed Sharon Moore as executive vice president of global quality and medical affairs.
John Saul, senior vice president of primary manufacturing and engineering for GlaxoSmithKline, has been elected president of the Chemical Industries Association (CIA).
Amsterdam Molecular Therapeutics has made two management changes. Piers Morgan has been appointed chief financial officer and Hans Preusting, director of process development and manufacturing, has taken responsibility for operations and project management.
Hans Juergen Wernicke took over as chairman of Dechema on 1 January 2010, replacing Alfred Oberholz. Wernicke was deputy chairman of Sued-Chemie in Munich. Ferdi Schueth follows Jens Weitkamp as deputy chairman. Kurt Wagemann succeeds Gerhard Kreysa as ceo. He has on Dechema's scientific staff since 1989 and deputy executive officer since 2007.
?Paul Burns has become vice president of global sales at Catalent Pharma Solutions and takes responsibility for developing Catalent's global sales strategy.
Amarin Corporation, a clinical-stage biopharmaceutical company focused on cardiovascular disease, says Joseph S Zakrzewski joined its Board of Directors as executive chairman on 1 January, 2010.
Symyx Technologies has made John Senaldi senior vice president of Symyx and president of its High Productivity Research (HPR) business.
